|
13 Nov 2018 |
NMPA Accepts Biosimilar New Drug Application for IBI303, a Biosimilar Candidate to Humira(R) (adalimumab)
|
|
13 Nov 2018 |
Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntington’s Disease at the Huntington Study Group’s 2018 Annual Meeting
|
|
13 Nov 2018 |
Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer
|
|
13 Nov 2018 |
FDA Grants Priority Review to Genentech’s Tecentriq in Combination With Abraxane for the Initial Treatment of People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
|
|
12 Nov 2018 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
|
|
11 Nov 2018 |
Celldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
|
|
11 Nov 2018 |
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
|
|
10 Nov 2018 |
Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory Board
|
|
10 Nov 2018 |
Visterra Initiates Phase 1 Clinical Study of VIS649
|
|
10 Nov 2018 |
Arcus Biosciences Presents Initial Data from the Phase 1 Dose-Escalation Study of AB122, its anti-PD-1 antibody, at the SITC 2018 Annual Meeting
|
|
10 Nov 2018 |
Harpoon Therapeutics Unveils ProTriTAC Platform: A Novel, Protease-Activated T Cell Engager Platform Designed to Access a Broad Landscape of Solid Tumor Targets
|
|
09 Nov 2018 |
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
|
|
09 Nov 2018 |
Study on Molecular Templates’ PD-L1 ETB with Antigen Seeding Technology Presented at SITC Annual Meeting
|
|
09 Nov 2018 |
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody
|
|
09 Nov 2018 |
Cue Biopharma Presents Foundational Data on Immuno-STAT Platform and CUE-101 at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
|
|
09 Nov 2018 |
CytomX Therapeutics Presents CX-072 Clinical Translational Data at 2018 SITC Annual Meeting
|
|
09 Nov 2018 |
Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy
|
|
09 Nov 2018 |
Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
|
|
09 Nov 2018 |
TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting
|
|
08 Nov 2018 |
Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data
|
|
08 Nov 2018 |
Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer
|
|
07 Nov 2018 |
Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma
|
|
07 Nov 2018 |
ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
|
|
07 Nov 2018 |
Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine"
|
|
07 Nov 2018 |
Oncobiologics Advances ONS-5010 into wet AMD Clinical Trial
|
